10865 Rancho Bernardo Rd
San Diego, CA 92127
Collaboration with the Colorado University and the Anschultz Medical Center has provided the foundation to develop novel technologies for more comprehensive studies in GI microbiota and clinical applications such as diagnostics and therapeutic development. In addition, Microtek holds key industry partnerships for developing medical devices and therapeutics. The laboratories located at Colorado University have state-of-the-art equipment and optimized methods to conduct in vitro characterization of microelectronic sensors/samplers and in vivo validation in preclinical animal models.
Currently, Microtek is focused on development and commercialization efforts for proprietary technologies (µTek™ Devices)
- GI Delivery µCapsule: Microtek is developing a miniaturized microelectronic controlled oral drug delivery system. The GI µCapsule will allow programmed release of therapeutic doses.
- GI µBiota µCapsule: Microtek’s GI µBiota Capsule will allow the collection of microbiota samples from different parts of the GI tract.
- µIT Device: An efficient intratracheal (IT) delivery system is often a limiting factor for therapeutics to be administered via the lung airways. Microtek’s μIT Device will provide an optimized delivery system to support pre-clinical animal studies in therapeutic development for lung diseases.
Therapeutic Discovery and Development
In conjunction with the University of Colorado Anschutz Medical Campus, Microtek is also developing targeted therapeutics. We use state-of-the-art equipment and procedures to discover new chemical entities (NCEs) or new biological entities (NBEs) with therapeutic potential, for integration into our microelectronic technologies.
Microtek’s collaborative projects with University of Colorado will focus on development of targeted therapeutics. We currently utilize proprietary high-throughput technologies and methods to identify NCEs and NBEs from botanical sources, and validate therapeutic efficacy in cell culture and animal models of different disease pathways. We also incorporate pharmaceutical biotechnology approaches to target therapeutic activity to the injured organ or tissue. The long term goal is to integrate these therapeutics with microelectronic technologies.